Patents by Inventor Hani Gabra

Hani Gabra has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cancer therapeutic methods utilizing OPCML fragment
    Patent number: 11857624
    Abstract: A method of treating a patient having a cancer in which HER2, HER4, FGFR1, EPHA2 and/or FGFR3 is upregulated and/or in which HER2, HER4, FGFR1, EPHA2 and/or FGFR3 mediated-signaling is upregulated, the method comprising administering to the patient a compound comprising or consisting of an OPCML polypeptide (SEQ ID NO: 1), or a fragment thereof which comprises at least one Ig domain of OPCML, or a variant thereof having at least 90% sequence identity with the OPCML polypeptide or the fragment thereof, or a nucleic acid molecule which encodes the OPCML polypeptide or fragment or variant thereof.
    Type: Grant
    Filed: May 22, 2020
    Date of Patent: January 2, 2024
    Assignee: PAPYRUS THERAPEUTICS, INC.
    Inventor: Hani Gabra
  • 1H-PYRAZOLO[3,4-D]PYRIMIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PLATINUM-RESISTANT CANCER
    Publication number: 20230064189
    Abstract: The invention relates to compounds of formula (I) and related compounds and their use in the treatment of cancer, especially platinum resistant cancer. The invention also provides a treatment comprising administration of a compound of formula (I) and a platinum containing drug.
    Type: Application
    Filed: December 18, 2020
    Publication date: March 2, 2023
    Inventors: Caroline LOW, Albert JAXA-CHAMIEC, Paula CUNNEA, Hani GABRA, Evan STRONACH, Catherine TRALAU-STEWART
  • CANCER METHODS
    Publication number: 20200353080
    Abstract: A method of treating a patient having a cancer in which HER2, HER4, FGFR1, EPHA2 and/or FGFR3 is upregulated and/or in which HER2, HER4, FGFR1, EPHA2 and/or FGFR3 mediated-signaling is upregulated, the method comprising administering to the patient a compound comprising or consisting of an OPCML polypeptide (SEQ ID NO: 1), or a fragment thereof which comprises at least one Ig domain of OPCML, or a variant thereof having at least 90% sequence identity with the OPCML polypeptide or the fragment thereof, or a nucleic acid molecule which encodes the OPCML polypeptide or fragment or variant thereof.
    Type: Application
    Filed: May 22, 2020
    Publication date: November 12, 2020
    Inventor: Hani Gabra
  • System and method for voltage measurements on biological tissues
    Patent number: 10670551
    Abstract: The present invention relates to a system and method useful for determining the voltage of biological tissues and therefore to detect whether such tissues are cancerous.
    Type: Grant
    Filed: August 25, 2016
    Date of Patent: June 2, 2020
    Assignee: Imperial College of Science, Technology and Medicine
    Inventors: Christina Fotopoulou, Emmanuel Drakakis, Hani Gabra, Martyn Boutelle
  • Cancer methods
    Patent number: 10660955
    Abstract: A method of treating a patient having a cancer in which HER2, HER4, FGFR1, EPHA2 and/or FGFR3 is upregulated and/or in which HER2, HER4, FGFR1, EPHA2 and/or FGFR3 mediated-signaling is upregulated, the method comprising administering to the patient a compound comprising or consisting of an OPCML polypeptide (SEQ ID NO: 1), or a fragment thereof which comprises at least one Ig domain of OPCML, or a variant thereof having at least 90% sequence identity with the OPCML polypeptide or the fragment thereof, or a nucleic acid molecule winch encodes the OPCML polypeptide or fragment or variant thereof.
    Type: Grant
    Filed: April 6, 2017
    Date of Patent: May 26, 2020
    Inventor: Hani Gabra
  • A System And Method For Voltage Measurements On Biological Tissues
    Publication number: 20180252666
    Abstract: The present invention relates to a system and method useful for determining the voltage of biological tissues and therefore to detect whether such tissues are cancerous.
    Type: Application
    Filed: August 25, 2016
    Publication date: September 6, 2018
    Inventors: Christina Fotopoulou, Emmanuel Drakakis, Hani Gabra, Martyn Boutelle
  • CANCER METHODS
    Publication number: 20180015163
    Abstract: A method of treating a patient having a cancer in which HER2, HER4, FGFR1, EPHA2 and/or FGFR3 is upregulated and/or in which HER2, HER4, FGFR1, EPHA2 and/or FGFR3 mediated-signaling is upregulated, the method comprising administering to the patient a compound comprising or consisting of an OPCML polypeptide (SEQ ID NO: 1), or a fragment thereof which comprises at least one Ig domain of OPCML, or a variant thereof having at least 90% sequence identity with the OPCML polypeptide or the fragment thereof, or a nucleic acid molecule winch encodes the OPCML polypeptide or fragment or variant thereof.
    Type: Application
    Filed: April 6, 2017
    Publication date: January 18, 2018
    Inventor: Hani Gabra
  • Cancer methods
    Patent number: 9649378
    Abstract: A method of treating a patient having a cancer in which HER2, HER4, FGFR1, EPHA2 and/or FGFR3 is upregulated and/or in which HER2, HER4, FGFR1, EPHA2 and/or FGFR3 mediated-signaling is upregulated, the method comprising administering to the patient a compound comprising or consisting of an OPCML polypeptide (SEQ ID NO: 1), or a fragment thereof which comprises at least one Ig domain of OPCML, or a variant thereof having at least 90% sequence identity with the OPCML polypeptide or the fragment thereof, or a nucleic acid molecule which encodes the OPCML polypeptide or fragment or variant thereof.
    Type: Grant
    Filed: April 15, 2011
    Date of Patent: May 16, 2017
    Inventor: Hani Gabra
  • CANCER METHODS
    Publication number: 20130171133
    Abstract: A method of treating a patient having a cancer in which HER2, HER4, FGFR1, EPHA2 and/or FGFR3 is upregulated and/or in which HER2, HER4, FGFR1, EPHA2 and/or FGFR3 mediated-signaling is upregulated, the method comprising administering to the patient a compound comprising or consisting of an OPCML polypeptide (SEQ ID NO: 1), or a fragment thereof which comprises at least one Ig domain of OPCML, or a variant thereof having at least 90% sequence identity with the OPCML polypeptide or the fragment thereof, or a nucleic acid molecule which encodes the OPCML polypeptide or fragment or variant thereof.
    Type: Application
    Filed: April 15, 2011
    Publication date: July 4, 2013
    Applicant: IMPERIAL INNOVATIONS LIMITED
    Inventor: Hani Gabra
  • CANCER
    Publication number: 20120207755
    Abstract: The invention provides methods of diagnosis, prognosis and treatment of cancer related to the OBCAM and NTM genes. The methods are particularly suited to ovarian and colorectal cancers.
    Type: Application
    Filed: February 17, 2012
    Publication date: August 16, 2012
    Applicant: Cancer Research Technology Limited
    Inventors: Grant Clark Sellar, Hani Gabra
  • CANCER
    Publication number: 20100311045
    Abstract: The invention provides methods of diagnosis, prognosis and treatment of cancer related to the OBCAM and NTM genes. The methods are particularly suited to ovarian and colorectal cancers.
    Type: Application
    Filed: October 30, 2009
    Publication date: December 9, 2010
    Applicant: Cancer Research Technology Limited
    Inventors: Grant Clark Sellar, Hani Gabra
  • Cancer
    Patent number: 7771930
    Abstract: The invention provides methods of diagnosis, prognosis and treatment of cancer related to the OBCAM and NTM genes. The methods are particularly suited to ovarian and colorectal cancers.
    Type: Grant
    Filed: June 20, 2002
    Date of Patent: August 10, 2010
    Assignee: Cancer Research Technology Limited
    Inventors: Grant Clark Sellar, Hani Gabra
  • Cancer
    Publication number: 20040241682
    Abstract: The invention provides methods of diagnosis, prognosis and treatment of cancer related to the OBCAM and NTM genes. The methods are particularly suited to ovarian and colorectal cancers.
    Type: Application
    Filed: June 21, 2004
    Publication date: December 2, 2004
    Inventors: Grant Clark Sellar, Hani Gabra
  • Diagnosis, prognosis and treatment of cancer related to the Barx2 gene
    Publication number: 20030087243
    Abstract: 5Surprisingly, it has been found that the Barx2 gene is mutated in ovarian cancer. The invention provides methods of diagnosis, prognosis and treatment of cancer related to the Barx2 gene.
    Type: Application
    Filed: December 12, 2001
    Publication date: May 8, 2003
    Inventors: Barry D. Nelkin, Hani Gabra, Grant C. Sellar, Janet E. V. Watson, David John Porteous